Takeda Starts Restructuring after Nycomed Acquisition

The Japanese company will consolidate its R&D sites and functions, cutting its global workforce by approximately 2,800 by the end of fiscal 2015.

Takeda Pharmaceutical is restructuring by consolidating site operations and integrating legacy Nycomed operations.

Takeda will align Nycomed's former operation structures and processes with the Takeda global headquarters in Japan and the newly defined organizations of the chief commercial officer, headquartered in Zurich, Switzerland, and chief medical and scientific officer, headquartered in Deerfield, IL, and its expanded affiliate network worldwide.

The Japanese company will consolidate its R&D sites and functions, cutting its global workforce by approximately 2,800 (2,100 in Europe and 700 in the U.S.) by the end of fiscal 2015 across the functions of R&D, commercial, operations and G&A, the cost of which is estimated at approximately 70 bill